##STR00001##

The present invention relates to novel fragrance compounds of general formula (I) which exhibit a Sandalwood-like fragrance and which are derivable from campholenic aldehyde derivates according to general formula (II). Furthermore, the present invention discloses compositions comprising one or more of the inventive fragrance compounds. The invention also relates to the use of such compounds or fragrance compositions comprising one or more of the compounds according to the invention as an odorant or or improving the fixation of a fragrance compound or a fragrance composition. Furthermore, the present invention refers to the use of such compounds or compositions for the preparation of a perfumed products as well as perfumed products as such.

The present disclosure relates to a novel method, expression vectors, and host cells for producing abienol by converting geranylgeranyl diphosphate (GGPP) to abienol in the presence of a combination of a class II diterpene synthase and a bifunctional class I/II abienol synthase.

The present invention refers to acetates possessing woody creamy sandalwood olfactory properties. The invention further refers to fragrance compositions and consumer products comprising them.

The present disclosure relates to methods and intermediates useful for preparing a compound of formula I. ##STR00001##
or a co-crystal, solvate, salt or combination thereof.

The present disclosure relates to methods and intermediates useful for preparing a compound of formula I.

##STR00001##

or a co-crystal, solvate, salt or combination thereof.

Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.

Provided are sulfonamide compounds having formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.

The present invention relates to novel fragrance compounds derived from campholenic aldehyde according to general Formula (II) or from the cyclopropanated campholenic aldehyde according to general Formula (III), or to compositions comprising one or more such fragrance compounds. The invention also relates to methods for preparing these compounds and to particular intermediates which are used in the preparation processes according to the present invention. It also pertains to a method for producing, enhancing or modifying a sandalwood odor in a formulation. The invention also relates to the use of such compounds or fragrance compositions comprising one or more compounds according to the invention as an odorant or for improving the fixation of a fragrance compound or a composition comprising a fragrance compound or for preparing perfumed products. Finally, the invention relates to corresponding perfumed products.

A plasma etching method according to an embodiment is a method for etching a silicon-containing film by using plasma of a fluorocarbon gas. The fluorocarbon gas includes at least one selected from a first fluorocarbon which has a main chain of six or more carbons bonded in a linear manner, the main chain having a structure of single bond and double bond alternately joined, a second fluorocarbon which has a main chain of six or more carbons bonded in a linear manner, the main chain having a structure of single bond and triple bond alternately joined, and a third fluorocarbon which has a main chain of five or more carbons bonded in a linear manner, the main chain having a structure which includes double bond and triple bond.

Disclosed are a series of compounds or their tautomers having a general structure represented by Formula Ia, Ib, IIa, IIb, or IIc and pharmaceutically acceptable salts thereof. The present disclosure also relates to pharmaceutical compositions comprising said compounds or tautomers. The present disclosure further relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis comprising administering to a subject in need thereof a therapeutically effective amount of Formula Ia, Ib, IIa, IIb, or IIc compounds or tautomers.